New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Journal of Clinical Oncology2012Vol. 30(36), pp. 4541–4549
Citations Over TimeTop 1% of 2012 papers
Giovanni Palladini, Angela Dispenzieri, Morie A. Gertz, Shaji Kumar, Ashutosh Wechalekar, Philip N. Hawkins, Stefan Schönland, Ute Hegenbart, Raymond L. Comenzo, Efstathios Kastritis, Meletios Α. Dimopoulos, Arnaud Jaccard, Catherine Klersy, Giampaolo Merlini
Abstract
This study identifies and validates new criteria for response to first-line treatment in AL amyloidosis, based on their association with survival in large patient populations, and offers surrogate end points for clinical trials.
Related Papers
- → Analysis of Multiple Bands on Serum Protein Immunofixation Electrophoresis: Challenge in Interpretation of Clonality in a Patient with Light Chain–Predominant Multiple Myeloma(2021)8 cited
- → Multiple sclerosis: use of light-chain typing to assist diagnosis(2001)22 cited
- Use of kappa and lambda chain quantitation for the detection of immunoglobulin abnormalities in serum.(1987)
- → Atypical Migration in Serum Immunofixation of Immunoglobulin A with Masked kappa Light Chains: a Case Report and Review of the Literature(2023)
- → Mass spectrometric‐based assessment of the serum kappa to lambda immunoglobulin light chain ratio (κ:λ) in dogs with immunoglobulin secretory diseases(2023)